Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Mar 28:13:1180965.
doi: 10.3389/fonc.2023.1180965. eCollection 2023.

Editorial: Insights in head and neck cancer: 2021

Willem Lybaert  1 , Jan B Vermorken  2   3
Affiliations
Editorial

Editorial: Insights in head and neck cancer: 2021

Willem Lybaert et al. Front Oncol. .
No abstract available

Keywords: artificial intelligence diagnostic radiology; biomarkers immunotherapy; nasopharyngeal carcinoma; papillary thyroid cancer; parotid tumors; targeting p53.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Comment on

  • Editorial on the Research Topic Insights in head and neck cancer: 2021

References

    1. Harrington KJ, Burtness B, Greil R, Soulieres D, Tahara M, de Castro G, Jr, et al. Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: Updated results of the phase III KEYNOTE-048 study. J Clin Oncol (2023) 41:790–802. doi: 10.1200/JCO.21.02508 - DOI - PMC - PubMed
    1. Lee NY, Ferris RL, Psyrri A, Haddad RI, Tahara M, Bourhis J, et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: A randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol (2021) 22(4):450–62. doi: 10.1016/S1470-2045(20)30737-3 - DOI - PubMed
    1. Bourhis J, Tao Y, Sun X, Sire C, Martin L, Liem X, et al. Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial. Ann Oncol (2021) 32(suppl_5):S1283–346. doi: 10.1016/annonc/annonc741 - DOI
    1. Machiels J, Tao Y, Burtness B, Tahara M, Rischin D, Alves GV, et al. Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC). Abstract LBA5 presented at ESMO Meeting (2022). doi: 10.1016/j.annonc.2022.08.029 - DOI
    1. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med (2008) 359(11):1116–27. doi: 10.1056/NEJMoa0802656 - DOI - PubMed

Publication types